MRNA therapy trial for rare acidemia halted early
NCT ID NCT04899310
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested an mRNA therapy called mRNA-3705 in 18 people with a rare genetic condition called methylmalonic acidemia, which causes harmful acid buildup. The therapy aimed to help the body produce a missing enzyme to lower acid levels. The trial was terminated early, so final conclusions about safety and effectiveness are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mRNA-3705 (a messenger RNA therapy that helps the body produce a missing enzyme)
What this could lead to
If successful, this could lead to a treatment that reduces harmful MMA levels in people with methylmalonic acidemia, potentially easing disease burden.
What could go wrong
The trial was terminated early with only 18 participants, so results are limited. As an early-phase study, safety and effectiveness are not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METHYLMALONIC ACIDEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Erasmus MC
Rotterdam, 3015 AA, Netherlands
-
Hospital For Sick Children
Toronto, Ontario, M5G 1X8, Canada
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Cruces
Barakaldo, 48903, Spain
-
Hôpital Necker - Enfants Malades
Paris, 75015, France
-
Lucile Packard Children's Hospital at Stanford
Palo Alto, California, 94304, United States
-
Royal Manchester Children's Hospital
Manchester, M13 9WL, United Kingdom
-
Stollery Children's Hospital University of Alberta
Edmonton, Alberta, T6G 2R7, Canada
-
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
UCLA Medical Center
Los Angeles, California, 90095, United States
-
Universitair Medisch Centrum Utrecht
Utrecht, 3584 CX, Netherlands